… endpoint for phase I dose escalation trials evaluating non-cytotoxic therapies can include …
help with phase I study dose selection of the non-cytotoxic drug. However, pharmacokinetic …

… Our findings demonstrate that approximately 50% of classic dose-escalating phase 1
trials investigating non-cytotoxic drugs actually identified the DLT. Nevertheless, it appears …

… high doses, while their potential risk at relatively low doses has … effects of AgNPs at non-cytotoxic
doses. We selected two … also analyzed in parallel at the same dose levels as AgNPs. …

… in the present work the effects of subtoxic doses of gemcitabine on a representative model of
a … to anti-cancer drug is detectable at non-cytotoxic doses, and secondly, if the same effects …

… As a result, ADs in the doses 100-fold lower than cytostatic … Indeed, the application of
non-cytotoxic doses of an AD melphalan … Thus, ADs at non-cytotoxic concentrations exert …

… in ultra-low, non-cytotoxic doses were previously shown to … applied in ultra-low, non-cytotoxic
doses on the efficiency of … in ultra-low, non-cytotoxic doses may potentially enhance the …

… of TiO 2 -NPs with cellular autophagy at non-cytotoxic doses. We used then uncoated TiO 2
-… to define the non-cytotoxic levels. Here we report that TiO 2 -NPs dose may shift the effects …

… dose, (b) the toxicity of the agent increases with increasing dose, and (c) there is a dose with
… For a targeted, non-cytotoxic agent, researchers and clinicians still obviously use the third …

Identifying cell response to a chemotherapy drug treatment, in particular at the single cell
level, is an important issue in patient management. This study aims at evaluating the effect of …

… between in-vitro dose and serum concentrations, … non cytotoxic dose) which itself was
observed to be immunosuppressive. The immunosuppressive effects of SB at the non-cytotoxic …